ClinicalTrials.gg
RecruitingNCT06225752Updated Oct 30, 2026

Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis

A Phase 3 interventional study of Probucol and Placebo probucol in Ischemic Stroke and TIA, sponsored by First Affiliated Hospital of Wannan Medical College. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by First Affiliated Hospital of Wannan Medical College · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,452
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
15th of 566
5,452 · median 271
Started
2024
with 102 others
Phase 3
111 of 754
65 open now
Primary completion
2028-04
later than 308 of 399 live
Registered
428th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 15th largest by planned enrollment of the 566 interventional ones that give a count, is one of 103 that started in 2024, is one of 111 in phase 3, reaches primary completion later than 308 of the 399 other live ones, and was the 428th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis.

Read the detailed description

This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis. During the study period, 5452 patients at intermediate risk for ischemic stroke or TIA will be enrolled from 100 centers.To evaluate whether probucol, as compared with placebo, reduces the risk of recurrent stroke in patients at high risk for ischemic stroke or TIA within 7 days of onset.Patients in one arm will receive probucol initiated with a dose of 1000 mg per day on days 1 through 30, and continuing with 500 mg per day after day 31, and those in the other arm will receive an equivalent placebo drug. Study visits will be performed on the day of randomization, at discharge, at day 90 and at 1 year and then followed up annually until the occurrence of the endpoint event or the end of the study. In addition, patients will be followed up at any time when new clinical symptoms of the neurologic system and suspicious events occur, including worsening of the original ischemic event and the appearance of new transient or persistent neurologic symptoms.

03

Conditions studied

  • Ischemic Stroke
  • TIA

Keywords

  • Probucol
  • Recurrent stroke
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.40 years or older than 40 years; 2.Ischemic stroke or (TIA); 3.Within 7 days from onset to randomization; 4.Main intracranial or extracranial arteries supplying the ischemic event region are narrowed by more than 50%; 5. signed.

Exclusion criteria

Exclusion Criteria:

  1. Presumed cardiac source of embolus, such as atrial fibrillation, prosthetic cardiac valve, endocarditis or patent foramen ovale;
  2. Stroke/ due to arterial dissection, angioplasty, or vascular surgery;
  3. Usage of probucol within 30 days before randomization;
  4. Known allergy or sensitivity or intolerance to probucol;
  5. Myocardial disease within the past 30 days, including myocardial infarction, myocarditis;
  6. With ventricular tachycardia, bradycardia, tip-twist ventricular tachycardia;
  7. With Q-Tc interval prolongation, or currently using drugs that may cause Q-Tc interval prolongation (male Q-Tc>450ms, female Q-Tc>470ms);
  8. Cardiac syncope or unexplained syncope;
  9. Impaired hepatic ( or AST > twice the ) or kidney (creatinine exceeding 1.5 times of the upper limit of normal range or less than 50 ml/min) function at randomization;
  10. Anemia ( \<10g/dL), thrombocytopenia ( count \<100×109/L) or leucopenia (white blood cell \<3×109/L) at randomization;
  11. Planned surgery or interventional treatment requiring cessation of the study drug during the study;
  12. Participating in another clinical trial with an drug or device concurrently or during the last 30 days;
  13. Pregnant or lactating women; Pregnant, currently trying to become pregnant, or of and not using ;
  14. Severe non-cardiovascular comorbidity with a of less than 1 years;
  15. Serious drug or alcohol abuse in the past 1 year;
  16. Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders, or to be an unsuitable candidate for the study for any other considered by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,452 participants (estimated)

Study arms

  • Experimental
    Probucol Group

    The study drug should be started as soon as possible within 7 days after symptom onset.

    Drug: Probucol

  • Placebo comparator
    Placebo Probucol Group

    The study drug should be started as soon as possible within 7 days after symptom onset.

    Drug: Placebo probucol

Interventions

  • Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)

  • DrugPlacebo probucol

    Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)

06

What researchers measure

Primary outcomes

  1. Recurrent stroke event

    Ischemic or hemorrhagic stroke

    Time frame: within 1 year

Secondary outcomes

  1. Recurrent ischemic stroke event

    Incidence of any new ischemic stroke

    Time frame: within 1 year

  2. Composite vascular events

    Including ischemic stroke, hemorrhagic stroke, myocardial infarction and vascular death

    Time frame: within 1 year

  3. Poor functional outcome

    Defined as a modified Rankin Scale (mRS) score ≥3(The mRS Scale is used to evaluate the recovery of neurological function in stroke patients. It consists of a seven-point scale, with Grade 0 indicating no symptoms at all. Grade 1 represents the presence of symptoms but without significant disability, allowing for the performance of regular jobs and activities. Grade 2 signifies mild disability where individuals are unable to perform all work and activities but can manage personal affairs independently. Grade 3 indicates moderate disability requiring assistance from others for walking without aid. Grade 4 denotes severe disability where individuals cannot walk unassisted and are unable to care for their own needs. Grade 5 represents severe disability with bedridden status, incontinence, and necessitating continuous care round-the-clock. Finally, Grade 6 signifies death.)

    Time frame: within 1 year

  4. All-cause mortality

    Death from any cause

    Time frame: within 1 year

Other outcomes

  1. Change in levels of oxidized low-density lipoprotein cholesterol (Ox-LDL)

    Ox-LDL is a component specific to the atherosclerotic lesion area that is not present in normal arterial vascular tissue and is elevated in atherosclerotic strokes

    Time frame: within 1 year

  2. Change in the rate of responsible vessel stenosis

    Stenosis of the responsible vessel at enrollment \>50%

    Time frame: within 1 year

  3. Adverse events

    The difference in the proportion of adverse events (AEs) between Probucol and the placebo group

    Time frame: within 1 year

  4. Severe adverse events

    The difference in the proportion of serious adverse events (SAEs) between Probucol and the placebo group;

    Time frame: within 1 year

07

Study locations

1 of 1 sites recruiting
  • The First Affliated Hospital of Wannan Medical College
    Wuhu, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Apr 2028, 46 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 46 months is above that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Apr 2026 → Apr 2028 and completion Oct 2026 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2024
First posted
Jan 26, 2024
StartActual
Jun 15, 2024
Primary completionEst.
Apr 30, 2028was Apr 2026
CompletionEst.
Oct 31, 2028was Oct 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 30, 2026→Apr 30, 2028
Oct 30, 2026
Study completion
Oct 31, 2026→Oct 31, 2028
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Apr 30, 2026→Apr 30, 2028
    Study completion Oct 31, 2026→Oct 31, 2028
    + 5 other changes: identifiers, verification date, responsible party, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06225752
Lead sponsor
First Affiliated Hospital of Wannan Medical College
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Jun 15, 2024
Primary completion
Apr 30, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probucol

Start the discussion